HCL Technologies and University of California, Berkeley to Partner on advanced Health Technology Collaborative Laboratory
Sunnyvale, Calif. and Noida, India – January 27, 2021 – HCL Technologies (HCL), a leading global technology company, today announced a collaboration with University of California, Berkeley to create a Health Technology Collaborative Laboratory (“CoLab”) housed in the Blum Center for Developing Economies on the university’s campus in Berkeley, California. The CoLab is being launched over the backdrop of the COVID-19 global pandemic created an urgent need for timely access to therapeutics and diagnostics with telemedicine and telesurgery are more important than ever. As a founding member of the CoLab, HCL is contributing $750,000 over the course of three years.
The CoLab’s multidisciplinary teams will work on health technology innovations to meet the challenges in a new age of healthcare. These activities will include rapid problem-solving, prototyping and testing of breakthrough healthcare technologies. This unique environment will bring together stakeholders in healthcare (patients, clinicians, regulators and insurers), the business community and investors to create and commercialize solutions from initial concept through the stages of prototyping, systems architecture and scalable distribution. Uniting global experts, technology and new approaches have proven key to addressing treatment and containment during the current pandemic and will be an important model for addressing future health challenges.
“As a responsible global technology leader, we are proud to contribute and support the creation of macro-scale solutions to healthcare issues for a better future for all,” said GH Rao, President, Engineering and R&D Services, HCL Technologies. “We’re honored to support UC Berkeley in this initiative, especially as the healthcare industry is undergoing tremendous transformation. As a founding member, HCL will have the opportunity to contribute to promising solutions and projects underway and looks forward to engaging the CoLab Ecosystem to develop new and unique health technology solutions for the future.”
“HCL’s commitment, combined with its vision for technology innovation and its global reach, will allow us to realize the goals of the CoLab quickly,” said Daniel Fletcher, Associate Director for Research of the Blum Center, Purnendu Chatterjee Chair of Bioengineering, and Director of the CoLab.
HCL continues to spearhead innovation and investments across the global health technology industry, and in recent times has provided significant contributions in the United States to the CDC Foundation, United Way, Gates Foundation and Feeding America to enable and advance healthcare solutions. HCL’s recent investments in multiple innovation and delivery centers in the US will further create jobs and bring focus to solving critical social, medical and economic challenges posed by the pandemic.
About HCL Technologies
HCL Technologies (HCL) empowers global enterprises with technology for the next decade, today. HCL’s Mode 1-2-3 strategy, based on its deep-domain industry expertise, client-centricity and entrepreneurial culture of Ideapreneurship™, enables businesses to transform into next-gen enterprises.
HCL offers its services and products through three business units: IT and Business Services (ITBS), Engineering and R&D Services (ERS) and Products & Platforms (P&P). ITBS enables global enterprises to transform their businesses through offerings in the areas of applications, infrastructure, digital process operations and next generation digital transformation solutions. ERS offers engineering services and solutions in all aspects of product development and platform engineering. P&P provides modernized software products to global clients for their technology and industry specific requirements. Through its cutting-edge co-innovation labs, global delivery capabilities and broad global network, HCL delivers holistic services in various industry verticals, categorized as Financial Services, Manufacturing, Technology and Services, Telecom and Media, Retail and CPG, Life Sciences and Healthcare, and Public Services.
As a leading global technology company, HCL takes pride in its diversity, social responsibility, sustainability, and education initiatives. For the 12 months ended December 31, 2020 HCL had consolidated revenue of US$ 10.02 billion. Its 159,682 Ideapreneurs operate out of 50 countries. For more information, visit www.hcltech.com
Certain statements in this release are forward-looking statements, which involve a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from those in such forward-looking statements. All statements, other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to the statements containing the words 'planned', 'expects', 'believes’,’ strategy', 'opportunity', 'anticipates', 'hopes' or other similar words. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding impact of pending regulatory proceedings, fluctuations in earnings, our ability to manage growth, intense competition in IT services, business process outsourcing and consulting services including those factors which may affect our cost advantage, wage increases in India, customer acceptances of our services, products and fee structures, our ability to attract and retain highly skilled professionals, our ability to integrate acquired assets in a cost-effective and timely manner, time and cost overruns on fixed-price, fixed-timeframe contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, the success of our brand development efforts, liability for damages on our service contracts, the success of the companies /entities in which we have made strategic investments, withdrawal of governmental fiscal incentives, political instability, legal restrictions on raising capital or acquiring companies outside India, and unauthorized use of our intellectual property, other risks, uncertainties and general economic conditions affecting our industry. There can be no assurance that the forward-looking statements made herein will prove to be accurate, and issuance of such forward-looking statements should not be regarded as a representation by the Company, or any other person, that the objective and plans of the Company will be achieved. All forward-looking statements made herein are based on information presently available to the Management of the Company and the Company does not undertake to update any forward-looking statement that may be made from time to time by or on behalf of the Company.
For further details, please contact:
Anne Coyle, US
Elka Ghudial, Europe
Devneeta Pahuja, India and APAC